Why We Love Personalized Depression Treatment (And You Should Too!) > 자유게시판

Personalized Depression Treatment

Traditional treatment and medications are not effective for a lot of people who are depressed. Personalized treatment could be the answer.

Cue is a digital intervention platform that transforms passively acquired smartphone sensor data into personalized micro-interventions that improve mental health. We analysed the best-fit personalized ML models for each subject using Shapley values to identify their feature predictors and uncover distinct features that are able to change mood over time.

Predictors of Mood

Depression is a major cause of mental illness around the world.1 Yet only half of those with the condition receive treatment. To improve the outcomes, doctors must be able identify and treat patients who are most likely to respond to certain treatments.

A customized depression in elderly treatment treatment plan can aid. Utilizing mobile phone sensors, an artificial intelligence voice assistant and other digital tools researchers at the University of Illinois Chicago (UIC) are working on new alternative ways to treat depression to determine which patients will benefit from which treatments. Two grants totaling more than $10 million will be used to discover biological and behavior predictors of response.

The majority of research to date has focused on clinical and sociodemographic characteristics. These include demographics like gender, age and education, as well as clinical characteristics such as symptom severity, comorbidities and biological markers.

While many of these aspects can be predicted from the data in medical records, few studies have utilized longitudinal data to study the causes of mood among individuals. They have not taken into account the fact that mood varies significantly between individuals. Therefore, it is crucial to devise methods that allow for the analysis and measurement of individual differences between mood predictors and treatment effects, for instance.

The team's new approach uses daily, in-person evaluations of mood and lifestyle variables using a smartphone app called AWARE, a cognitive evaluation with the BiAffect app and electroencephalography -- an imaging technique that monitors brain activity. This allows the team to create algorithms that can detect various patterns of behavior and emotion that differ between individuals.

In addition to these modalities the team also developed a machine-learning algorithm to model the changing variables that influence each person's mood. The algorithm combines the individual characteristics to create an individual "digital genotype" for each participant.

This digital phenotype was correlated with CAT-DI scores, which is a psychometrically validated symptom severity scale. The correlation was weak, however (Pearson r = 0,08, P-value adjusted by BH 3.55 x 10 03) and varied widely between individuals.

Predictors of symptoms

Depression is among the world's leading causes of disability1, but it is often underdiagnosed and undertreated2. Depressive disorders are often not treated due to the stigma attached to them, as well as the lack of effective treatments.

To allow for individualized treatment, identifying predictors of symptoms is important. Current prediction methods rely heavily on clinical interviews, which are unreliable and only detect a few characteristics that are associated with depression.

Machine learning can improve the accuracy of the diagnosis and treatment of depression by combining continuous, digital behavioral patterns gathered from sensors on smartphones with a validated mental health tracker online (the Computerized Adaptive Testing Depression Inventory CAT-DI). Digital phenotypes can be used to capture a large number of distinct behaviors and activities that are difficult to capture through interviews, and allow for high-resolution, continuous measurements.

The study comprised University of California Los Angeles students who had mild depression treatments to severe depression symptoms who were taking part in the Screening and Treatment for Anxiety and Depression program29 that was developed as part of the UCLA Depression Grand Challenge. Participants were routed to online assistance or in-person clinics according to the severity of their depression. Participants who scored a high on the CAT DI of 35 65 were allocated online support with a peer coach, while those with a score of 75 patients were referred to in-person clinics for psychotherapy.

Participants were asked a series of questions at the beginning of the study concerning their psychosocial and demographic characteristics as well as their socioeconomic status. The questions asked included age, sex and education, marital status, financial status as well as whether they divorced or not, the frequency of suicidal thoughts, intentions or attempts, as well as the frequency with which they consumed alcohol. The CAT-DI was used to rate the severity of depression symptoms on a scale ranging from zero to 100. The CAT-DI tests were conducted every week for those who received online support and weekly for those receiving in-person care.

Predictors of lithium treatment for Depression Reaction

The development of a personalized depression treatment is currently a top research topic and a lot of studies are aimed to identify predictors that enable clinicians to determine the most effective medications for each person. In particular, pharmacogenetics identifies genetic variants that influence how the body's metabolism reacts to antidepressants. This lets doctors choose the medications that will likely work best for each patient, while minimizing time and effort spent on trial-and-error treatments and avoiding any side negative effects.

Another promising approach is building models of prediction using a variety of data sources, combining data from clinical studies and neural imaging data. These models can be used to identify which variables are the most likely to predict a specific outcome, like whether a drug will improve symptoms or mood. These models can be used to predict the response of a patient to a treatment, which will help doctors to maximize the effectiveness.

A new generation of machines employs machine learning techniques like supervised and classification algorithms, regularized logistic regression and tree-based methods to integrate the effects of multiple variables and increase the accuracy of predictions. These models have been demonstrated to be useful in predicting outcomes of treatment for example, the response to antidepressants. These approaches are gaining popularity in psychiatry and it is expected that they will become the norm for the future of clinical practice.

In addition to the ML-based prediction models research into the mechanisms behind depression is continuing. Recent research suggests that depression is related to dysfunctions in specific neural networks. This suggests that an individualized treatment for mild depression treatment will be based upon targeted therapies that restore normal function to these circuits.

Internet-based interventions are an option to accomplish this. They can provide more customized and personalized experience for patients. A study showed that an internet-based program helped improve symptoms and led to a better quality life for MDD patients. Furthermore, a randomized controlled study of a customized approach to treating depression showed an improvement in symptoms and fewer adverse effects in a large percentage of participants.

Predictors of side effects

In the treatment of depression a major challenge is predicting and identifying which antidepressant medication will have no or minimal negative side effects. Many patients experience a trial-and-error approach, using various medications prescribed before finding one that is effective and tolerable. Pharmacogenetics is an exciting new way to take an efficient and targeted approach to choosing antidepressant medications.

There are a variety of variables that can be used to determine the antidepressant that should be prescribed, such as gene variations, patient phenotypes such as gender or ethnicity, and comorbidities. However finding the most reliable and reliable predictive factors for a specific treatment will probably require controlled, randomized trials with much larger samples than those normally enrolled in clinical trials. This is due to the fact that it can be more difficult to determine moderators or interactions in trials that comprise only one episode per person rather than multiple episodes over a long period of time.

Furthermore, predicting a patient's response will likely require information on the comorbidities, symptoms profiles and the patient's personal perception of effectiveness and tolerability. At present, only a handful of easily measurable sociodemographic variables as well as clinical variables seem to be reliable in predicting the response to MDD. These include gender, age, race/ethnicity, SES, BMI and the presence of alexithymia.

Many challenges remain in the application of pharmacogenetics to treat depression. First it is necessary to have a clear understanding of the genetic mechanisms is required, as is an understanding of what constitutes a reliable predictor for treatment response. Ethics like privacy, and the ethical use of genetic information must also be considered. In the long term pharmacogenetics can provide an opportunity to reduce the stigma that surrounds mental health care and improve treatment outcomes for those struggling with depression. However, as with any other psychiatric treatment, careful consideration and planning is required. At present, it's best to offer patients various depression medications that are effective and urge them to speak openly with their physicians.